Overexpression of c-erbB2 and Its Relationship with Chemotherapy in Breast Cancer / 대한암학회지
Journal of the Korean Cancer Association
;
: 450-456, 1998.
Article
Dans Coréen
| WPRIM
| ID: wpr-70025
ABSTRACT
PURPOSE:
c-erbB2 encodes 185 kDa oncoprotein with tyrosine kinase activity and has homology to the epidermal growth factor receptor. c-erbB2 proto-oncogene is found to be overexpressed in approximately 20 to 30% of primary breast cancer and has been associated with poor prognosis and lower response to conventional chemotherapy. MATERIALS ANDMETHODS:
We perfonned a study on 40 infiltrating ductal breast cancers treated with primary surgery and adjuvant chemotherapy. We investigated c-erbB2 expression by immunohistochemistry in paraffin-embedded tissue using polyclonal antipeptide antibody(DAKO). We evaluated the relationships between its expression and the results after over 6 cycles of adjuvant chemotherapy including cyclophosphamide, methotrexate and 5-FU.RESULTS:
The median age at diagnosis was 43 years and the median follow-up time was 47.3 months. Thirteen(32.1%) of 40 patients showed the c-erbB2 overexpression in the external domains of protein. There were no correlations among c-erbB2 amplification and other prognostic factors such as hormonal receptors, histologic grade and tumor size. Estrogen receptor and progesterone receptor showed tendency of inverse correlation with c-erbB2 overexpression but it was not statistically significant(p>0.05). c-erbB2 positive patients showed shorter disease free survival compared to c-erbB2 negative patients in univariate analysis(p0.05).CONCLUSION:
These findings suggest that overexpression of c-erbB2 may be a marker of poor response to adjuvant chemotherapy with CMF regimen and may be an indicator of more aggressive therapy.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Pronostic
/
Protein-tyrosine kinases
/
Proto-oncogènes
/
Région mammaire
/
Tumeurs du sein
/
Immunohistochimie
/
Récepteurs à la progestérone
/
Méthotrexate
/
Études de suivi
/
Traitement médicamenteux adjuvant
Type d'étude:
Etude diagnostique
/
Étude observationnelle
/
Étude pronostique
Limites du sujet:
Humains
langue:
Coréen
Texte intégral:
Journal of the Korean Cancer Association
Année:
1998
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS